As the prevalence of obesity continues to climb, clinicians are seeing an increasing number of men with symptoms of low testosterone. However, many of these patients are started on testosterone replacement therapy (TRT) without appropriate evaluation for reversible causes, particularly obesity. This not only overlooks the root metabolic dysfunction but also carries potential long-term risks such as infertility, erythrocytosis, and prostate-related complications. This session offers a unique dual perspective grounded in both hormone physiology and obesity management.

Through clinical case presentations drawn from real-world practice, attendees will learn how to apply evidence-based strategies to the diagnosis and management of obesity-associated hypogonadism (also referred to as MOSH—male obesity-associated secondary hypogonadism). Emphasis will be placed on how to differentiate obesity-related hypogonadism from primary or other secondary causes, how to interpret hormonal labs in the context of obesity (including the role of SHBG), and how to avoid inappropriate or premature use of TRT. The session will also highlight new and emerging data on the role of obesity pharmacotherapy in improving testosterone levels, further reinforcing the value of treating the root cause rather than simply replacing the hormone. Recent clinical trials showing hormonal recovery with GLP-1 receptor agonists and other anti-obesity medications will be discussed in depth.

By the end of the session, attendees will walk away with a deeper understanding of the interplay between obesity and the hypothalamic-pituitary-gonadal axis, improved diagnostic confidence, and a clear, practical framework for managing male patients presenting with symptoms of low testosterone in the context of obesity.

CME/CE Expiration Date: 4/12/29

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.